Skip to main content
Equibles
PROK logo

PROK · Prokidney Corp.

Track PROK — free

Use PROK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PROK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.80 -0.04 (-2.17%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current operating plan, we do not believe our existing cash and cash equivalents and marketable securities as of June 30, 2026, will be sufficient to fund our obligations for the 12 months following the issuance of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q on August 10, 2026. Accordingly, substantial doubt exists about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$556.27M
Shares
302.32M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.80 Open$1.88 Day$1.80–1.93 52W close$1.33–3.30 Avg vol 30d1.2M Short int20.7M · 6.9% float · 17.7d Short vol91% Last earningsMay 10, 2024 DataJun 2021–Sep 2026 Filing10-Q · Aug 10

Up next

Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$818,000
Trailing 12 months
Net income (TTM)
−$84.16M
Trailing 12 months
Revenue growth YoY
-32.1%
Year over year
Operating margin
-21,664.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-28.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$74.87M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-14.8%
Trailing year
Short interest
6.9%
Latest settlement · 17.7 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −7%
below
Price vs 50-day avg +8%
above
RSI (14) 53
neutral
MACD trend Positive
52-week position 24%
mid-range
Momentum
relative strength
Weak
1-month return +28%
trailing
6-month return −7%
trailing
YTD return −20%
this year
Relative strength −25%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +22 funds added
Insider flow Distributing
Net -$1.1M over 90 days · 100% sells
Short interest Falling
6.86% of float · ▼ -3.5% MoM · 17.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
71 holders — mid 5-yr range
Squeeze score 68
elevated · 0–100
Fundamentals
Fair
Revenue growth +1075%
Y/Y
Free cash flow $-135.3M
Quant / Vol
risk profile
Very High
Volatility 74%
annualized · 1-yr
Max drawdown −60%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−7% Bearish
Price vs 50-day avg
+8% Bullish
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
24% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +22 funds added
Insider flow Distributing
Net -$1.1M over 90 days · 100% sells
Short interest Falling
6.86% of float · ▼ -3.5% MoM · 17.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
71 holders — mid 5-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 24% Range high $3
vs 200-day avg -7% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PROK
Prokidney Corp.
this stock
$556.27M -19.6% +1075.0% — 6.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.67B +1.2% +20.8% 19.6 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
CSLLY
Csl Ltd
 $57.41B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
71
% held
15.9%
Net QoQ
+5.3M sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
62
View
Short & Settlement
Short Interest Falling
Shares short
20.7M
Days to cover
17.7d
Change
-757.2K sh
View
Short Volume
Short vol %
91%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
6.5K
Value
$9.1K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
43.2%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.1M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-69.0M
EPS diluted
$-0.23
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
11
View
Proposed Sales
Value
$1.8M
Shares
675.2K
Filed
Nov 12, 2025
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
PROK -6.3% +28.1% -6.7% -4.8% -19.6%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -5.1% +29.9% -24.6% -4.4% -31.7%
Key facts CIK 1850270 CUSIP 74291D104 13F (30d) 39 filings 39 filers Visit website Investor relations